PMID- 38313077
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240206
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 14
DP  - 2023
TI  - Pharmacological therapy of metabolic dysfunction-associated steatotic liver 
      disease-driven hepatocellular carcinoma.
PG  - 1336216
LID - 10.3389/fphar.2023.1336216 [doi]
LID - 1336216
AB  - In light of a global rise in the number of patients with type 2 diabetes mellitus 
      (T2DM) and obesity, non-alcoholic fatty liver disease (NAFLD), now known as 
      metabolic dysfunction-associated fatty liver disease (MAFLD) or metabolic 
      dysfunction-associated steatotic liver disease (MASLD), has become the leading 
      cause of hepatocellular carcinoma (HCC), with the annual occurrence of 
      MASLD-driven HCC expected to increase by 45%-130% by 2030. Although MASLD has 
      become a serious major public health threat globally, the exact molecular 
      mechanisms mediating MASLD-driven HCC remain an open problem, necessitating 
      future investigation. Meanwhile, emerging studies are focusing on the utility of 
      bioactive compounds to halt the progression of MASLD to MASLD-driven HCC. In this 
      review, we first briefly review the recent progress of the possible mechanisms of 
      pathogenesis and progression for MASLD-driven HCC. We then discuss the 
      application of bioactive compounds to mitigate MASLD-driven HCC through different 
      modulatory mechanisms encompassing anti-inflammatory, lipid metabolic, and gut 
      microbial pathways, providing valuable information for future treatment and 
      prevention of MASLD-driven HCC. Nonetheless, clinical research exploring the 
      effectiveness of herbal medicines in the treatment of MASLD-driven HCC is still 
      warranted.
CI  - Copyright (c) 2024 Wang, Fleishman, Li, Li, Ren, Chen and Ding.
FAU - Wang, Yumin
AU  - Wang Y
AD  - Department of Respiratory and Critical Care Medicine, Aerospace Center Hospital, 
      Peking University Aerospace School of Clinical Medicine, Beijing, China.
FAU - Fleishman, Joshua S
AU  - Fleishman JS
AD  - Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, 
      St. John's University, Queens, NY, United States.
FAU - Li, Tongda
AU  - Li T
AD  - Department of Traditional Chinese Medicine, Beijing Geriatric Hospital, Beijing, 
      China.
FAU - Li, Yulin
AU  - Li Y
AD  - Department of Respiratory and Critical Care Medicine, Aerospace Center Hospital, 
      Peking University Aerospace School of Clinical Medicine, Beijing, China.
FAU - Ren, Zhao
AU  - Ren Z
AD  - Department of Pharmacy, Aerospace Center Hospital, Peking University Aerospace 
      School of Clinical Medicine, Beijing, China.
FAU - Chen, Jichao
AU  - Chen J
AD  - Department of Respiratory and Critical Care Medicine, Aerospace Center Hospital, 
      Peking University Aerospace School of Clinical Medicine, Beijing, China.
FAU - Ding, Mingchao
AU  - Ding M
AD  - Department of Peripheral Vascular Intervention, Aerospace Center Hospital, Peking 
      University Aerospace School of Clinical Medicine, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240119
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC10834746
OTO - NOTNLM
OT  - hepatocellular carcinoma
OT  - metabolic dysfunction-associated steatotic liver disease
OT  - natural products
OT  - non-alcoholic fatty liver disease
OT  - treatment
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2024/02/05 06:43
MHDA- 2024/02/05 06:44
PMCR- 2024/01/19
CRDT- 2024/02/05 04:31
PHST- 2023/11/10 00:00 [received]
PHST- 2023/12/31 00:00 [accepted]
PHST- 2024/02/05 06:44 [medline]
PHST- 2024/02/05 06:43 [pubmed]
PHST- 2024/02/05 04:31 [entrez]
PHST- 2024/01/19 00:00 [pmc-release]
AID - 1336216 [pii]
AID - 10.3389/fphar.2023.1336216 [doi]
PST - epublish
SO  - Front Pharmacol. 2024 Jan 19;14:1336216. doi: 10.3389/fphar.2023.1336216. 
      eCollection 2023.